Thomas Gajewski to Cancer Vaccines
This is a "connection" page, showing publications Thomas Gajewski has written about Cancer Vaccines.
Connection Strength
2.189
-
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019 11 08; 7(1):295.
Score: 0.558
-
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 2010 Jul-Aug; 16(4):399-403.
Score: 0.292
-
Update on vaccines for solid tumors. Clin Adv Hematol Oncol. 2004 Mar; 2(3):158-9.
Score: 0.188
-
Integrating IL-12 into therapeutic cancer vaccines. Cancer Chemother Biol Response Modif. 2002; 20:343-9.
Score: 0.162
-
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond. Clin Diagn Lab Immunol. 2000 Mar; 7(2):141-4.
Score: 0.143
-
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int J Cancer. 1999 Jan 18; 80(2):324-33.
Score: 0.132
-
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells. Int Immunol. 1997 Sep; 9(9):1259-69.
Score: 0.120
-
Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol. 1995 Aug; 2(4):211-25.
Score: 0.104
-
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol. 2011 Apr; 38(2):236-42.
Score: 0.077
-
Immune suppression in the tumor microenvironment. J Immunother. 2006 May-Jun; 29(3):233-40.
Score: 0.055
-
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
Score: 0.054
-
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
Score: 0.053
-
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003 Jun 15; 21(12):2342-8.
Score: 0.045
-
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol. 2001 May; 13(5):625-32.
Score: 0.039
-
The p815 mastocytoma tumor model. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.4.
Score: 0.039
-
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001 Mar; 7(3 Suppl):895s-901s.
Score: 0.038
-
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 1999 May 05; 81(3):428-37.
Score: 0.034
-
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. J Transl Med. 2012 May 28; 10:108.
Score: 0.021
-
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May 12; 9:60.
Score: 0.019
-
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8.
Score: 0.017